Novel inhibitors of T315I mutant BCR-ABL1 tyrosine kinase for chronic myeloid leukemia disease through fragment-based drug design

Keyphrases

• Fragment Based Drug Design 100%
• Chronic Myeloid Leukemia 100%
• Leukemia Disease 100%
• Novel Inhibitors 100%
• BCR-ABL1 Tyrosine Kinase 100%
• T315I mutation 100%
• Tyrosine Kinase 100%
• Philadelphia Chromosome 100%
• Binding Score 50%
• Binding Affinity 50%
• Recombination 50%
• Chromosome 9 50%
• BCR-ABL 50%
• Malignant Transformation 50%
• Warriors 50%
• Tyrosine Kinase Activity 50%
• Chromosomal Translocation 50%
• Genetic Abnormalities 50%
• Philadelphia 50%
• New Drug Candidate 50%
• Chromosome 22 50%
• ADME-Tox 50%
• BCR Gene 50%
• Therapeutic Intervention 50%

Biochemistry, Genetics and Molecular Biology

• Myeloid 100%
• Receptor Tyrosine Kinase 100%
• Tyrosine Kinase 100%
• Philadelphia Chromosome 66%
• Genetics 33%
• Chromosome 9 33%
• Kinase 33%
• Phosphotransferase 33%
• Malignant Transformation 33%
• Chromosome 22 33%
• ABL (Gene) 33%
• Binding Affinity 33%
• Chromosomal Translocation 33%
• BCR (Gene) 33%